MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561222 | Name: Trimebutine Maleate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Trimebutine Maleate is a drug with antimuscarinic and weak mu opioid agonist effects. Trimebutine Maleate modulates the calcium and potassium channels, relieves abdominal pain in patients with irritable bowel syndrome. Trimebutine Maleate is used for treatment of irritable bowel syndrome and other gastrointestinal disorders.

Chemical Structure

Trimebutine Maleate
Trimebutine Maleate
CAS#34140-59-5

Theoretical Analysis

MedKoo Cat#: 561222

Name: Trimebutine Maleate

CAS#: 34140-59-5

Chemical Formula: C26H33NO9

Exact Mass:

Molecular Weight: 503.55

Elemental Analysis: C, 62.02; H, 6.61; N, 2.78; O, 28.60

Price and Availability

Size Price Availability Quantity
1g USD 190.00
5g USD 300.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Trimebutine Maleate; Debridat; Polibutin; Modulon; Dromostat; EINECS 251-845-9; Ibutin; Polibutin; TM 906; Trimebutine maleate, Trimedat
IUPAC/Chemical Name
[2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate Maleate
InChi Key
FSRLGULMGJGKGI-BTJKTKAUSA-N
InChi Code
InChI=1S/C22H29NO5.C4H4O4/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5;5-3(6)1-2-4(7)8/h8-14H,7,15H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
SMILES Code
O=C(OCC(C1=CC=CC=C1)(N(C)C)CC)C2=CC(OC)=C(OC)C(OC)=C2.O=C(O)/C=C\C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 503.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Trimebutine: abuse, addiction and overdose. Prescrire Int. 2013 Oct;22(142):241-2. PubMed PMID: 24298588. 2: Long Y, Liu Y, Tong J, Qian W, Hou X. Effectiveness of trimebutine maleate on modulating intestinal hypercontractility in a mouse model of postinfectious irritable bowel syndrome. Eur J Pharmacol. 2010 Jun 25;636(1-3):159-65. doi: 10.1016/j.ejphar.2010.03.037. Epub 2010 Apr 2. PubMed PMID: 20371236. 3: Cho KH, Choi YK, Kang JH, Choi HG, Yong CS, Park YJ. Development of a novel combination tablet containing trimebutine maleate and mosapride citrate for the treatment of functional dyspepsia. Int J Pharm. 2010 Nov 15;400(1-2):145-52. doi: 10.1016/j.ijpharm.2010.08.047. Epub 2010 Sep 6. PubMed PMID: 20826201. 4: Lee SY, Kim MY, Kang SY, Song WJ, Kang HR. A case of trimebutine-induced anaphylaxis. Allergol Int. 2011 Dec;60(4):555-6. doi: 10.2332/allergolint.10-CR-0289. PubMed PMID: 22113162. 5: Lee HT, Kim BJ. Trimebutine as a modulator of gastrointestinal motility. Arch Pharm Res. 2011 Jun;34(6):861-4. doi: 10.1007/s12272-011-0600-7. PubMed PMID: 21725804. 6: Takenaga H, Magaribuchi T, Nosaka K, Tamaki H. [Effects of trimebutine maleate on the gastrointestinal motility in conscious dogs]. Nihon Yakurigaku Zasshi. 1982 Oct;80(4):271-8. Japanese. PubMed PMID: 7152394. 7: Tan W, Zhang H, Luo HS, Xia H. Effects of trimebutine maleate on colonic motility through Ca²+-activated K+ channels and L-type Ca²+ channels. Arch Pharm Res. 2011 Jun;34(6):979-85. doi: 10.1007/s12272-011-0615-0. Epub 2011 Jul 2. PubMed PMID: 21725819. 8: Aktas A, Caner B, Ozturk F, Bayhan H, Narin Y, Mentes T. The effect of trimebutine maleate on gastric emptying in patients with non-ulcer dyspepsia. Ann Nucl Med. 1999 Aug;13(4):231-4. PubMed PMID: 10510878. 9: Rahman MZ, Ahmed DS, Mahmuduzzaman M, Rahman MA, Chowdhury MS, Barua R, Ishaque SM. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Mymensingh Med J. 2014 Jan;23(1):105-13. PubMed PMID: 24584382. 10: Yu LN, Li FM. [HPCE determination of trimebutine maleate in rat plasma and its pharmacokinetics]. Yao Xue Xue Bao. 2001 Feb;36(2):131-3. Chinese. PubMed PMID: 12579881. 11: Kang SH, Jeen YT, Koo JS, Koo YS, Kim KO, Kim YS, Kim SY, Moon JS, Park JJ, Baek IH, Park SC, Lee SJ, Lee JH, Choung RS, Choi SC. [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study]. Korean J Gastroenterol. 2013 Nov;62(5):278-87. Korean. PubMed PMID: 24262593. 12: Wang H, Zhou H, Horimoto S, Jiang J, Mayumi T, Hu P. Quantitative determination of trimebutine maleate and its three metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 5;779(2):173-87. PubMed PMID: 12361732. 13: Couturier D, Chaussade S, Grandjouan S. [Effects of trimebutine on motility of the small intestine in humans]. Presse Med. 1989 Feb 15;18(6):303-7. French. PubMed PMID: 2537973. 14: Okano H, Saeki S, Inui A, Kawai Y, Ohno S, Morimoto S, Ohmoto A, Nakashima T, Miyamoto M, Okita M, et al. Effect of trimebutine maleate on emptying of stomach and gallbladder and release of gut peptide following a solid meal in man. Dig Dis Sci. 1993 May;38(5):817-23. PubMed PMID: 8482179. 15: Nagasaki M, Kurosawa H, Naito K, Tamaki H. Allosteric interaction of trimebutine maleate with dihydropyridine binding sites. Eur J Pharmacol. 1990 Jul 31;189(1):71-6. PubMed PMID: 2171963. 16: Zhong YQ, Zhu J, Guo JN, Yan R, Li HJ, Lin YH, Zeng ZY. [A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndrome]. Zhonghua Nei Ke Za Zhi. 2007 Nov;46(11):899-902. Chinese. PubMed PMID: 18261269. 17: Kotake H, Kinugawa T, Hirai S, Fukugi M, Hasegawa J, Mashiba H. Effect of trimebutine maleate on sinus node pacemaker activity of the rabbit. Eur J Pharmacol. 1987 Dec 15;144(3):327-30. PubMed PMID: 2450035. 18: Morisawa T, Hasegawa J, Tanabe K, Watanabe A, Kitano M, Kishimoto Y. Effects of trimebutine maleate on delayed rectifier K+ currents in guinea-pig ventricular myocytes. J Pharm Pharmacol. 2000 Apr;52(4):403-8. PubMed PMID: 10813550. 19: Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Nov 30. Available from http://www.ncbi.nlm.nih.gov/books/NBK350043/ PubMed PMID: 26985535. 20: Naska S, Yuzwa SA, Johnston AP, Paul S, Smith KM, Paris M, Sefton MV, Datti A, Miller FD, Kaplan DR. Identification of Drugs that Regulate Dermal Stem Cells and Enhance Skin Repair. Stem Cell Reports. 2016 Jan 12;6(1):74-84. doi: 10.1016/j.stemcr.2015.12.002. Epub 2015 Dec 24. PubMed PMID: 26724904; PubMed Central PMCID: PMC4719140.